HOUSTON -- More than 60% of patients with relapsed/refractory large B-cell lymphoma (LBCL) had objective responses to the bispecific antibody epcoritamab (Epkinly), according to updated results from a ...
Please provide your email address to receive an email when new articles are posted on . Most patients in the high-risk study population had some response to treatment. All high-grade treatment-related ...
Chemotherapy is the primary treatment for non-Hodgkin lymphoma, though people may also receive it with immunotherapy. Chemotherapy remains the first-line treatment for non-Hodgkin lymphoma (NHL), a ...
A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) ...
Description: Clinical study evaluating the normal tissue tolerance to radiation therapy following induction chemotherapy in casts with intra-abdominal high-grade lymphoma. Eligibility: Cats with a ...
Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial As of September 2, 2024, 129 patients with ...
High-dose methotrexate (HDMTX; > 500 mg/m 2) is an important component of lymphoma therapy. Serum MTX monitoring at 48 hours is the standard approach to identify those at increased risk of developing ...
Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results